

RECORD OF TELEPHONE CONVERSATION

Submission Information

Application Type	BLA
STN	125428/0.0
Review Office	OVRR
Applicant	Dynavax Technologies Corporation / Lic. # 1883
Product	Hepatitis B Vaccine (Recombinant), Adjuvanted
Trans-BLA Group:	No

Telecon Details

Telecon Date/Time	23-JUN-2017 04:09 PM
Author	AGNIHOTHAM, SUDHAKAR
EDR	No
Post to Web	Yes
Outside Phone Number	
FDA Originated?	No
Communication Categories	IR - Information Request
Related STNs	None
Related PMCs	None
Telecon Summary	Email clarification to submit the response to the IR sent on 06/23/17 by 07/07/17 instead of the originally requested date of 07/14/17.
FDA Participants	Sudhakar Agnihothram, Katherine Berkousen, and Richard Daemer
Applicant Participants	Elaine Alambra, Senior Director, Regulatory Affairs

Telecon Body:

From: Agnihothram, Sudhakar [<mailto:Sudhakar.Agnihothram@fda.hhs.gov>]

Sent: Friday, June 23, 2017 1:07 PM

To: Elaine Alambra

RECORD OF TELEPHONE CONVERSATION

Cc: Berkhausen, Katherine; Daemer, Richard J.
Subject: RE: Information Request Re: STN 125428/0072

Hi Elaine,

I am writing with a clarification to the IR we sent this morning. Please submit your response to the IR by COB 07/07/17 instead of the originally requested date of 07/14/17. Please let us know if you have any questions.

Thanks, Sudhakar

From: Elaine Alambra [<mailto:EAlambra@dynavax.com>]
Sent: Friday, June 23, 2017 10:08 AM
To: Agnihothram, Sudhakar
Cc: Berkhausen, Katherine; Daemer, Richard J.
Subject: RE: Information Request Re: STN 125428/0072

Dear Sudhakar,

Acknowledged receipt.

Kind regards,

Elaine

Elaine Alambra • Senior Director, Regulatory Affairs • Dynavax Technologies Corporation ☎ Tel: 510-665-0474 ✉ email: ealambra@dynavax.com

From: Agnihothram, Sudhakar [<mailto:Sudhakar.Agnihothram@fda.hhs.gov>]
Sent: Friday, June 23, 2017 4:33 AM
To: Elaine Alambra
Cc: Berkhausen, Katherine; Daemer, Richard J.
Subject: Information Request Re: STN 125428/0072

Dear Elaine,

Please find our request for the following information.

Reference to previous submission - **BLA 125428/0072**

We noted that in your Risk Management Plan version 2.0 you have proposed a Pregnancy Registry to monitor pregnancy outcomes in women exposed to HEPLISAV during pregnancy (section 1.16.1.2.2.2-Pregnant or lactating women).

Please submit a Concept Protocol for the proposed Pregnancy Registry as well as the projected dates and their justification for final protocol submission, study completion and final report submission by **COB 07/14/2017**

RECORD OF TELEPHONE CONVERSATION

You may refer to the FDA Guidance for Establishing Pregnancy Registries at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071639.pdf

Please let us know if you have any questions.

Thanks,

Sudhakar

Sudhakar Agnihothram B.Pharm, Ph.D,
Primary Reviewer/ Regulatory Project Manager,
Division of Vaccine Related Product Applications,
Office of Vaccines Research and Review,
Center For Biologics Evaluation and Research,
10903, New Hampshire Avenue,
BLDG 71, 3215 C,
Silver Spring, Maryland, 20993.
Email: Sudhakar.Agnihothram@fda.hhs.gov
Ph: 301-348-3056

This email message is for the sole use of the intended recipient(s) and may contain confidential or privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. The content of this message is subject to access, review and disclosure by the sender's email system administrator.

This email message is for the sole use of the intended recipient(s) and may contain confidential or privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. The content of this message is subject to access, review and disclosure by the sender's email system administrator.
